Biotech Values

[biomaven0]

>>Run a large dose ranging trial at the same time as a large randomized trial in earlier line?

Agree, but that's not my only complaint. The whole idea of true 2nd-line is misguided at this point.

Much better to go after 2nd-gen failures (so call it 2.5-line). In other words 2nd-line if a 2nd-gen drug was used as front-line, otherwise 3rd-line. There they could very likely show convincing evidence, while a 1-year trial in true 2nd-line isn't going to convince anyone of long-term safety.

Peter